Abstract Vitamin D is associated with skeletal muscle physiology and function and may play a role in intramuscular inflammation, possibly via the vitamin D receptor (VDR). We conducted two studies to examine (1) whether serum 25-hydroxyvitamin D (25OHD) and/or intramuscular VDR protein concentrations are associated with intramuscular interleukin-6 (IL-6) and/or tumor necrosis factora (TNFa); and (2) whether 16-week supplementation with vitamin D 3 alters intramuscular IL-6 and/or TNFa. Potential-related signaling pathways were also examined. Muscle biopsies of 30 older, mobility-limited adults were obtained at baseline. A subset of 12 women were supplemented with either 4,000 IU/day of vitamin D 3 (N = 5) or placebo (N = 7), and biopsies were repeated at 16 weeks. Serum 25OHD was measured, and intramuscular VDR, IL-6, and TNFa gene expressions and protein concentrations were analyzed. Baseline serum 25OHD was not associated with intramuscular IL-6 or TNFa gene expression or protein concentration. Baseline intramuscular VDR protein concentration, adjusted for baseline serum 25OHD, was positively associated with intramuscular IL-6 gene expression (n = 28; p = 0.04), but negatively associated with intramuscular IL-6 protein (n = 18; p = 0.03). Neither intramuscular IL-6 nor TNFa gene expression was different between placebo (n = 7) or vitamin D 3 supplementation groups (n = 5) after 16 weeks (p = 0.57, p = 0.11, respectively). These data suggest that VDR is a better predictor than serum 25OHD concentration of intramuscular IL-6 gene and protein expressions. A similar relationship was not observed for TNFa expression. Further, supplementation with 4,000 IU vitamin D 3 per day does not appear to affect intramuscular IL-6 or TNFa gene expression after 16 weeks.
Introduction
Intramuscular inflammation has been demonstrated in a variety of skeletal muscle disorders [1, 2] and contributes to muscle loss and dysfunction in systemic inflammatory disorders, such as insulin resistance, type 2 diabetes mellitus, and cardiovascular disease [3] .
An inverse relationship between serum 25-hydroxyvitamin-D (25OHD) and markers of inflammation has been shown in obesity [4] , type 2 diabetes mellitus [5] , and cardiovascular disease [6] . Further, vitamin D 3 supplementation has been shown to result in a decreased innate immune response [7] , although results from other studies have been mixed [8, 9] .
Emerging evidence suggests that vitamin D may play a direct role in mediating inflammation within skeletal muscle [10, 11] . As skeletal muscle has been shown to produce and secrete proinflammatory cytokines, such as IL-6 [12] , an interaction between vitamin D and intramuscular inflammatory pathways is of particular interest. Although the literature examining this interaction is limited, the data indicate that increased concentrations of circulating 25OHD aid muscular recovery from injury [13] , and vitamin D 3 supplementation may reduce exerciseinduced intramuscular inflammation [10] and directly suppress intramuscular pathways of inflammation, particularly after exercise [11] . However, the mechanism by which vitamin D may directly impact human musclemediated inflammation is yet unclear.
Studies in other tissues, such as fibroblasts and breast cancer cells, suggest that vitamin D receptor (VDR) activation may regulate intracellular inflammation [14] [15] [16] . VDR may also be implicated in skeletal muscle-mediated inflammation as has been noted in other tissues, such as vascular endothelial cells [17] . Although there is some controversy [18] possibly resulting from differences between experimental protocols [19] , VDR has been shown to be expressed in skeletal muscle tissue [19] [20] [21] ; it appears to decrease with age [22] , and increase with vitamin D 3 supplementation [11, 19, 21] . VDR downstream signaling cascades in skeletal muscle have yet to be well characterized; however, recent animal model data suggest that inflammation pathways are altered after the administration of vitamin D. An investigation examining rats supplemented with vitamin D and exposed to high-intensity exercise demonstrated increased intramuscular VDR with concurrent reductions in signaling molecules p38 MAPK and components of the NFkB cascade which ultimately resulted in attenuation of intramuscular TNF-a and IL-6 [11] . While it has been posited that chronically decreased expression of VDR in aging skeletal muscle may play a role in decreased strength and functional ability, this emerging research suggests it may also have a role in intramuscular inflammation, possibly through non-genomic signaling events.
We hypothesized that serum 25OHD and intramuscular VDR gene expression and protein concentrations would be inversely related to inflammatory markers, IL-6 and TNFa. To investigate this hypothesis, we conducted a study to examine (1) the baseline association between serum 25OHD and intramuscular IL-6 or TNFa gene and protein concentrations, (2) the baseline association between intramuscular VDR gene expression or protein concentration with intramuscular IL-6 and TNFa gene and protein contents in older, mobility-limited adults. We also conducted a second study to assess changes in intramuscular IL-6 and TNFa after a 16-week supplementation of vitamin D 3 in older, mobility-limited women. As a secondary analysis, we examined p38 MAPK and NFkB phosphorylation cascades that have been implicated in interactions between serum 25OHD, intramuscular VDR, and inflammatory markers, IL-6 and TNFa.
Materials and methods

Subjects
Data for these studies were pooled from the baseline measurements of two larger randomized controlled studies for which inclusion and exclusion criteria are presented elsewhere [21, 23] . Specific characteristics of study subjects are presented in Table 1 . Only those subjects who provided a muscle biopsy (N = 30; male = 7; female = 23) were included in the analysis. Participants were mobility limited as determined by the short physical performance battery (SPPB \10) [24] and were not obese (BMI \30). In the longitudinal study, a subset of 12 women were either supplemented with 4,000 IU/day of vitamin D 3 (N = 5) or placebo (N = 7), and biopsies were repeated at 16 weeks. Both clinical studies were approved by the Institutional Review Board of the Tufts University Health Sciences Campus (Boston, MA).
Biochemical measures
Archived fasting blood samples were assessed at baseline and 16-week periods. Serum 25OHD was analyzed utilizing Diasorin, LIAISON Ò 25 OH vitamin D total assay. Vitamin D deficiency was defined as 25OHD serum concentrations below 12 ng/mL, insufficiency as 12-19 ng/ mL, and sufficiency C20 ng/mL [25] .
Muscle biopsy
Muscle biopsies were obtained from the vastus lateralis at the level of the mid-thigh under local anesthesia (1 % In the longitudinal analysis, student's t test was used to analyze differences in intramuscular IL-6 and TNFa mRNA fold changes between placebo and supplemented groups. Secondary correlational analyses were used to assess associations between VDR or 25OHD with intramuscular inflammatory markers and signaling molecules in the crosssectional study. Statistical significance was set at p B 0.05 for all analyses. Variables were each examined for normal distribution, and were log-transformed, if necessary, to better approximate normal distribution.
Results
Subject characteristics
Subjects from the two studies were pooled for the baseline cross-sectional analysis. Mean age (±SD) of the baseline sample (N = 30) was 78.2 ± 4.4 years, mean BMI was 27.0 ± 3.5 kg/m 2 , and mean serum 25OHD was 22.5 ± 10.6 ng/mL (range 9-53 ng/mL). A comparison between subjects from the two studies is presented in Table 1 .
Skeletal muscle IL-6 and TNFa gene expressions
Cross-sectional analysis
In the combined group at baseline, it should be noted that within subset 1, two subjects did not have their VDR protein concentration measured and were, thus, excluded from the cross-sectional analysis. Neither baseline 25OHD nor VDR gene expression (adjusted for baseline 25OHD) was associated with IL-6 gene expression (n = 28; p = 0.92 and p = 0.21, Fig. 1a, b respectively) . Neither baseline 25OHD nor VDR gene expression (adjusted for baseline 25OHD) was associated with TNFa gene expression (p = 0.68 and p = 0.18, Fig. 1d, e respectively) . However, in a multilinear regression model adjusted for serum 25OHD, intramuscular VDR protein concentration (log VDR) was positively associated with intramuscular IL-6 gene expression (Total Model R 2 = 0.15; p = 0.04, Fig. 1c ), but not with TNFa gene expression (p [ 0.18, Fig. 1f ).
Longitudinal analysis
At baseline, older, mobility-limited women (subset 1, N = 12) were classified as either vitamin D insufficient or deficient. After 16 weeks, all vitamin D-supplemented subjects were classified as vitamin D sufficient, while placebo subjects did not reach sufficient 25OHD levels [21] .
There was no significant difference between the fold changes of intramuscular IL-6 mRNA expression between the placebo (mean 0.45, 95 % CI 2.53, 3.43) and supplemented groups (mean 3.02, 95 % CI 7.21, 13.26; p = 0.57, Fig. 2b ).
IL-6 and TNFa protein concentration and signaling pathways
Cross-sectional analysis
In subset 2 (Table 1 ; N = 18) for which intramuscular IL-6 and TNFa protein was available for analysis by Western Blot, baseline serum 25OHD was not associated with intramuscular IL-6 protein concentration (p = 0.13, 
Discussion
This study found that intramuscular IL-6, a marker of inflammation, was associated with intramuscular VDR in older, mobility-limited adults. Intramuscular VDR protein concentration was positively associated with intramuscular IL-6 gene expression, but negatively associated with intramuscular IL-6 protein concentration. There was no significant change in intramuscular IL-6 gene expression after 16 weeks of vitamin D 3 supplementation. Because the sample size was small, it is premature to conclusively rule out possible contributions of serum 25OHD to intramuscular inflammation; however, we were able show noteworthy evidence that VDR may be associated with intramuscular IL-6 in human skeletal muscle.
Although traditionally assumed to be a marker of inflammation in serum, intramuscular IL-6 has also recently been termed a myokine and may be an emerging endocrine factor [26] shown to have several roles in skeletal muscle metabolism [27] in addition to participation in intramuscular inflammatory pathways [26, 28] . IL-6 is present in skeletal muscle at rest and becomes elevated with muscular contraction [29] . Of note, murine intramuscular IL-6 is attenuated by vitamin D supplementation, possibly via intramuscular VDR [11] . We hypothesized that IL-6 gene and protein expressions would be inversely associated with intramuscular VDR. However, our results demonstrated a contrasting relationship between VDR protein concentration and IL-6 gene expression versus protein concentration. One explanation could be that both VDR and IL-6 were measured intramuscularly, while 25OHD is measured from serum. Interestingly, however, a similar relationship has previously been reported with dietary glucose ingestion resulting in decreased intramuscular IL-6 protein release from exercising muscle with no change in IL-6 mRNA [30] . Further, other human myokines demonstrate differential effects between mRNA and protein expression upon stimulation [31, 32] . Finally, as VDR has been shown to have rapid non-genomic effects in skeletal muscle [33, 34] , there may be a signaling or inhibitory effect through which VDR protein itself may attenuate translation of IL-6 protein (Fig. 5) . It is possible that VDR protein decreases the present inflammatory response through a signaling process as noted in animal models [11] or affects other yet unidentified molecules which then initiate post-translational inhibitory effects as has been demonstrated by other myokines in skeletal muscle [35] .
We did not observe a relationship between intramuscular TNFa, intramuscular VDR, or serum 25OHD. Our results are consistent with those reported for vascular endothelial cells in middle-aged and older adults [17] . These authors concluded there was no involvement in vitamin D-related effects on endothelial cell inflammation with regard to TNFa. This disparate response between IL-6 and TNFa has previously been established in skeletal muscle in response to contraction where intramuscular IL-6 is produced independently of TNFa [35] . Finally, the parallel relationship between inflammatory cytokines traditionally noted in serum may not hold true within muscle given the unique emerging roles of IL-6 within muscle.
In order to assess possible signaling relationships between VDR and IL-6 gene expressions and protein concentration, we examined two key signaling pathways, p38 MAPK and NFjB. We did not find an association between serum 25OHD or intramuscular VDR with intramuscular NFjB or MAPK p38, although associations between NFjB and VDR did trend toward significance. While our sample size prohibits us from ruling out these pathways as a potential link between intramuscular inflammation and VDR, our results may suggest that any relationship may be outside this particular p38 MAPK pathway in human skeletal muscle. It is recommended that future studies with larger sample sizes re-examine these as well as alternative signaling pathways to determine the mechanistic relationship between intramuscular VDR and intramuscular IL-6. This is of interest due to the proposed non-inflammatory properties of IL-6 in skeletal muscle [26, 28] and the noted lack of association between serum 25OHD and IL-6 in our results. Our study had several strengths including our ability to examine both a cross-sectional sample of human biopsied muscle and a longitudinal model following vitamin D 3 supplementation versus placebo. Limitations of this study were that it had a small sample size and was a secondary analysis of data pooled from two studies. However, as our results demonstrate a significant association between human VDR and IL-6, there could be future clinical implications with regard to supplementation in vulnerable populations.
The results of our study lend evidence to the potential relationship between VDR and IL-6 in human skeletal muscle. We found that intramuscular VDR protein concentration is positively correlated with intramuscular IL-6 gene expression, but negatively associated with intramuscular IL-6 protein concentration in older, mobility-limited adults. Neither intramuscular VDR nor serum 25OHD appear to be associated with intramuscular TNFa in humans. These findings should be considered hypothesis generating and need to be confirmed in larger randomized trials specifically designed to examine intramuscular inflammation. Future studies are needed to examine the relationship between protein concentrations of VDR and IL-6 in skeletal muscle after supplementation, IL-6-related signaling pathways, and implications on muscle function. 5 Theoretical model of VDR interaction in attenuating intramuscular inflammation models are suggested via p38 MAPK and NFkB phosphorylation cascades, although further investigation must be completed in order to confirm, as our results demonstrated no association with these pathways despite prior-reported relationships
